Financial Data and Key Metrics Changes - In 2025, Tarsus Pharmaceuticals achieved over $450 million in full-year net sales, with Q4 net product sales at $151.7 million and a gross-to-net discount of 44% [3][20] - Total operating expenses for 2025 were $522.3 million, primarily due to commercial investments for the XDEMVY launch [20] - The company ended 2025 with approximately $418 million in cash, cash equivalents, and marketable securities, providing financial flexibility for growth [20] Business Line Data and Key Metrics Changes - XDEMVY, the FDA-approved therapeutic for Demodex blepharitis, has helped over 500,000 patients since its launch and is expected to reach blockbuster status with sales potential exceeding $2 billion [3][4] - The company plans to expand its pipeline with two clinical-stage programs: TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, targeting one to two new programs per year [4][5] Market Data and Key Metrics Changes - The U.S. market for Demodex blepharitis is estimated to have 25 million affected individuals, with significant growth potential as awareness and treatment options expand [7][8] - Tarsus has achieved over 90% coverage across commercial Medicare and Medicaid, enhancing patient access [9] Company Strategy and Development Direction - Tarsus aims to create and lead new categories in eye care by identifying diseases with clear root causes and unmet needs, applying the successful development and commercial playbook established with XDEMVY [4][5] - The company is focused on disciplined growth, leveraging existing infrastructure while responsibly allocating capital to extend its long-term growth trajectory [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of XDEMVY, citing strong fundamentals and a growing base of prescribers [7][34] - The company anticipates strong net product sales guidance for 2026 in the range of $670 million to $700 million, representing over 50% growth at the midpoint [21][22] Other Important Information - Tarsus is preparing for the Phase 2 trial of TP-04, expected to cost between $7 million and $10 million, and the Phase 2 trial of TP-05, estimated at $25 million to $30 million [25][72] - The company is also making progress with TP-03 for potential regulatory approval in Europe and Japan, with expectations for approval in China later this year [19] Q&A Session Summary Question: Can you provide more detail on expectations beyond Q1 for the $370 million-$400 million guidance? - Management indicated that Q1 is expected to be flat to slightly down due to typical seasonal dynamics, with a strong growth anticipated in Q2 [31][32] Question: What is driving the increased conviction for the $2 billion peak sales target? - The increase is attributed to the broadening prescriber base and deeper engagement with top-tier prescribers, alongside continued flawless execution in commercial efforts [40][41] Question: Can you elaborate on the DTC campaign and its ROI? - The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected, and management plans to maintain the $80 million spend while also investing in the sales force [45][46] Question: What are the expected costs for the ocular rosacea and Lyme disease studies? - The ocular rosacea study is expected to cost between $7 million and $10 million, while the Lyme disease study is projected to cost $25 million to $30 million [72]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jade Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 2836 83-137788 (Primary Standard Industrial Classification Code Number) 221 Crescent St., Building 23 Suite 105 Waltham, MA 02453 (781) 312-3013 (Address, including zip code, and telephone number, including area code, of regist ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 8, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Akston Biosciences Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 45-4562397 (I.R.S. Employer Identification ...

Table of Contents As filed with the Securities and Exchange Commission on September 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (609) 538-8200 (Name, Address, Including Zip Code, and Telephone Num ...

Core Viewpoint - Neurocrine Biosciences (NBIX) is a biopharmaceutical company focused on developing treatments for neurology and neuroendocrinology, with a strong commercial portfolio and an expanding pipeline [1] Group 1: Commercial Portfolio - The two most important commercial drugs for Neurocrine Biosciences are Ingrezza and another unnamed product [1]

Core Insights - GSK plc is a prominent biopharmaceutical company focused on developing specialty and general drugs, as well as vaccines [1] Financial Performance - GSK's Q1 2025 results demonstrated strong momentum, particularly in the specialty medicines segment [1] - The oncology performance of GSK was noted as excellent, indicating a robust growth area for the company [1]

As filed with the Securities and Exchange Commission on March 24, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 2223 Avenida de la Playa, # ...

As filed with the U.S. Securities and Exchange Commission on October 15, 2024. Registration No. 333-279771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its charter) ______________________________ Ontario, Canada 2834 98-1778211 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on December 21, 2023. Registration No. 333- GRI BIO, INC. (Exact name of registrant as specified in its charter) (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Adam Lenain, Esq. Melanie Ruthrauff Levy, Esq. Jason Miller, Esq. Mintz, Levin, Cohn, Ferris, Glo ...